Excision develops CRISPR-based therapies to cure viral infectious diseases. The company’s first targeted viral infection is HIV, with a pipeline to begin trials on treatments for Herpes Simplex Virus, JC Virus/PML andHepatitis B in the next ~2-3 years.

The Excision approach is the first technology in history to remove HIV genomes from animals and generate a functional cure for HIV.

‍

‍